Segments (Tables)

3 Months Ended

Mar. 31, 2022

Segment Adjusted EBITDA by reportable segment was as follows:


	Three Months Ended March 31,
	2022		2021
Biopharmaceuticals	$	(11,620)	$	(8,854)
Exemplar	3,558		1,806
Trans Ova	5,397		6,421
Segment Adjusted EBITDA for reportable segments	$	(2,665)	$	(627)

Revenues by reportable segment were as follows:


	Three Months Ended March 31, 2022
	Biopharmaceuticals		Exemplar		Trans Ova		Total
Revenues from external customers	$	84	$	5,429	$	26,508	$	32,021
Intersegment revenues	1,446		—		147		1,593
Total segment revenues	$	1,530	$	5,429	$	26,655	$	33,614


	Three Months Ended March 31, 2021
	Biopharmaceuticals		Exemplar		Trans Ova		Total
Revenues from external customers	$	178	$	3,257	$	21,076	$	24,511
Intersegment revenues	241		—		107		348
Total segment revenues	$	419	$	3,257	$	21,183	$	24,859

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:


	Three Months Ended March 31,
	2022		2021
Segment Adjusted EBITDA for reportable segments	$	(2,665)	$	(627)

Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	1,314		597
Add recognition of previously deferred revenue associated with upfront and milestone payments	1,446		307
Other expenses:
Interest expense	(2,069)		(4,539)
Depreciation and amortization	(3,292)		(3,523)
Loss on disposals of assets	(125)		(121)
Impairment losses	(482)		—

Stock-based compensation expense	(3,562)		(5,415)
Adjustment related to accrued bonuses paid in equity awards	1,698		—
Equity in net loss of affiliates	(1)		(3)
Other	—		(7)
Unallocated corporate costs	(10,060)		(8,194)
Eliminations	(1,511)		(371)
Consolidated net loss from continuing operations before income taxes	$	(19,309)	$	(21,896)

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:


	Three Months Ended March 31,
	2022		2021
Total segment revenues from reportable segments	$	33,614	$	24,859

Elimination of intersegment revenues	(1,593)		(348)
Total consolidated revenues	$	32,021	$	24,511